His PD-L1 Was 80%. The EGFR Result Put Targeted Therapy First

The portal printout sat in the middle of the table at a family meeting. Near the top of one page was the result everyone had noticed: PD-L1, 80%.

The patient was 63, and a biopsy had recently shown advanced nonsquamous non-small cell lung cancer, often shortened to NSCLC. Non-small cell lung cancer is the most common broad category of lung cancer. “Nonsquamous” describes how the cancer cells look under a microscope and helps determine which tests and treatments may be relevant.

His cancer had spread beyond the original lung tumor. The family understood that part, even if they were still absorbing it. What they could not place was the 80%.

A relative had written “high” beside it on the portal printout. Another result was still pending: broad molecular testing of the tumor. They had been told that this testing might find a mutation, and the family had started treating the two results as rival grades. If PD-L1 was already high, they wondered, could a mutation result somehow overrule it?

That confusion is common because both results can influence treatment, both may come from the same biopsy sample, and both appear in reports full of percentages and technical language. Yet they measure different features of the cancer.

What the 80% meant

PD-L1 is short for programmed death-ligand 1, a protein that can appear on the surface of tumor cells and some immune cells. The result usually reports the percentage of sampled tumor cells that show PD-L1 staining in the laboratory.

An 80% tumor proportion score means that about 80% of the tumor cells assessed in that sample stained for PD-L1. It does not mean the cancer is 80% advanced. It does not mean treatment has an 80% chance of working, and it does not measure how much cancer is in the body.

PD-L1 can help clinicians estimate whether a type of immunotherapy called a checkpoint inhibitor may be useful. Checkpoint inhibitors release some of the restraints that normally limit immune activity, allowing the immune system a better opportunity to recognize and attack cancer cells.

A high PD-L1 result may support discussing a checkpoint inhibitor, sometimes by itself and sometimes with chemotherapy, depending on the full clinical picture. The percentage is useful, but it is not a personal forecast. People whose tumors have high PD-L1 may respond differently, while some tumors with lower expression still respond.

The family had heard the word “eligible” and understood it as “chosen.” Those are not the same. A result can make a treatment an available option without making it the preferred first option once every other result is known.

His daughter put a finger beside the 80% on the portal printout. That number answered one question about the tumor’s interaction with the immune system. It did not answer every treatment question.

What the mutation result did

The molecular report arrived eight days later. A new page was added to the portal printout, and it listed an EGFR exon 19 deletion.

EGFR stands for epidermal growth factor receptor. It is a gene that gives cells instructions for making a protein involved in growth. Some lung cancers acquire a change in EGFR that keeps growth signals active. In this setting, that alteration can act as a driver mutation, meaning it helps power the cancer’s growth.

A tumor mutation is a change in the cancer cells’ genetic material. Many such changes have no established treatment attached to them. An “actionable” driver mutation is different: it may identify a treatment designed to interfere with the altered protein or the signal it produces.

That treatment is called targeted therapy. Unlike chemotherapy, which affects many rapidly dividing cells, a targeted drug is developed around a particular molecular feature. Finding an EGFR driver alteration can therefore shift the first treatment discussion toward an EGFR-targeted medicine.

The mutation result was not a better PD-L1 score. It did not replace 80% with a more powerful number. It supplied another kind of information, one that can be especially important when clinicians decide what to use first in advanced nonsquamous NSCLC.

Other established driver alterations can involve genes such as ALK, ROS1, BRAF, MET, RET, NTRK, KRAS or HER2. The meaning depends on the precise alteration, not only the gene name, and the set of changes linked to approved treatments continues to develop.

This is why broad testing matters. A report saying that one common mutation was absent does not necessarily show that the tumor lacks an actionable driver. The molecular panel, the amount and quality of tissue, and whether testing was completed all affect what the report can establish.

Why the order of results changed the conversation

At the first family meeting, the oncologist had the diagnosis and the high PD-L1 result, but the broad molecular report was pending. Immunotherapy was part of the conversation. It was not yet a finished plan.

Once the EGFR alteration appeared, targeted therapy moved to the front of the discussion. Research and treatment guidelines generally support using an appropriate targeted therapy first for advanced NSCLC with certain actionable drivers, even when PD-L1 is high, because these tumors often respond better to the matched targeted approach than to checkpoint immunotherapy alone.

There was another reason to care about sequence. “Sequence” can refer to the order in which test results arrive, but it can also mean the order in which treatments are given. Studies have found that certain targeted drugs used after checkpoint inhibitors may be associated with a greater risk of serious inflammatory side effects in some settings. The details vary by mutation, medicine and interval between treatments.

That does not make immunotherapy permanently irrelevant. Treatments may change as a cancer changes, and later decisions depend on response, side effects, new biopsy findings and the person’s health. At this meeting, however, the immediate issue was the opening treatment, not every treatment he might receive over the years.

Waiting eight days was possible because his treating team judged that his condition allowed time for the molecular result. Another person may have symptoms or complications that require treatment before every report is complete, and clinicians may have to make decisions with partial information. The timing cannot be separated from what is happening in the person’s body.

The family’s note beside PD-L1 had said “high.” Beside EGFR, someone had written “target.” Those two words finally kept the jobs separate on the portal printout.

A percentage and a target are not competing grades

PD-L1 is a biomarker, which means a measurable biological feature that may help predict how a cancer could behave or respond to treatment. A driver mutation is also a biomarker. Sharing that category does not make the tests interchangeable.

The PD-L1 percentage describes protein expression in the sampled cells. Molecular testing examines genetic changes in the tumor. One may support immunotherapy choices; the other may identify a matched targeted treatment that clinicians often consider first.

Both results also have limits. A biopsy captures tissue from one place and one point in time, while cancers can contain groups of cells with different features. Laboratory methods and sample quality matter. A result can guide a conversation without guaranteeing an outcome.

Testing may be performed on tumor tissue, blood or both. A blood-based test looks for fragments of tumor DNA circulating in the bloodstream and is sometimes called a liquid biopsy. Finding an actionable alteration in blood can be useful, but a negative blood result may occur because the tumor is releasing too little DNA to detect. Clinicians may still rely on tissue testing when it is available and adequate.

Most tumor mutations are acquired changes found in the cancer rather than changes inherited from a parent. In some circumstances, a finding can raise a separate question about inherited risk. A genetics professional can explain whether testing beyond the tumor report is relevant; the molecular page alone does not settle that issue.

What this piece cannot tell you

This story cannot show which treatment is best for any individual with NSCLC. It cannot interpret a specific pathology report, establish whether testing was complete or predict whether immunotherapy, targeted therapy or chemotherapy will work.

A thoracic medical oncologist can explain how PD-L1, molecular findings, the cancer’s extent and the person’s health fit together. The pathology or molecular testing team can clarify what sample was examined and whether any part of the analysis remained incomplete. Questions about inherited risk belong with a genetics professional rather than assumptions made from a portal page.

For this family, the useful change was smaller than certainty. The 80% stayed on the portal printout. It had not become wrong. The EGFR page changed what the team discussed first.

Questions people ask

Does high

PD-L1 mean immunotherapy should start immediately?

High PD-L1 can make checkpoint immunotherapy an important option, but it does not choose treatment by itself. In advanced nonsquamous NSCLC, clinicians commonly review molecular testing for actionable driver mutations before settling on the first plan, provided the person’s condition allows time for the remaining results.

Can a tumor have both high PD-L1 and a driver mutation?

Yes. The tests measure different tumor features, so a cancer can have high PD-L1 expression and an actionable alteration such as an EGFR mutation. In the composite story, the 80% PD-L1 result remained valid after the EGFR finding appeared; the later result changed how the two options were prioritized.

Does a driver mutation mean the cancer was inherited?

Usually, a driver mutation reported from tumor testing is an acquired change in the cancer cells, not proof of an inherited condition. Some findings may lead to a separate genetics review, which uses family history and, when appropriate, testing of non-tumor cells to address inherited risk.

How long can molecular testing take?

Turnaround varies with the sample, laboratory method and whether more tissue is needed. Reports may return separately rather than as one complete package, which can leave a treatment discussion temporarily unfinished. In this family, the pending status stayed circled on the portal printout until the molecular page appeared eight days later.